Last reviewed · How we verify
PCV 20
PCV 20 is a pneumococcal conjugate vaccine that stimulates immune responses against 20 serotypes of Streptococcus pneumoniae.
PCV 20 is a pneumococcal conjugate vaccine that stimulates immune responses against 20 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults, Prevention of pneumococcal pneumonia in adults.
At a glance
| Generic name | PCV 20 |
|---|---|
| Sponsor | Inventprise Inc. |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens (20 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
PCV 20 contains polysaccharide antigens from 20 different pneumococcal serotypes conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. The vaccine primes both humoral and cellular immunity to prevent invasive pneumococcal disease and pneumococcal pneumonia across a broader serotype coverage than earlier-generation pneumococcal conjugate vaccines.
Approved indications
- Prevention of invasive pneumococcal disease in adults
- Prevention of pneumococcal pneumonia in adults
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
- Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (PHASE1, PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Prediction and Prevention of Postoperative Mortality and Morbidity (NA)
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (PHASE2)
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |